AKT1 and prostate carcinoma: PKIB(cAMP-dependent protein kinase inhibitor beta) was reported as a key regulator of the PI3K/Akt pathway involved in tumor aggressiveness in NSCLC (non-small cell lung cancer) and prostate cancer (58, 59).